𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sa1106 Adalimumab Monotherapy Versus Combination Therapy With Adalimumab and Immunomodulators for Crohn's Disease: A Meta-Analysis

✍ Scribed by Kopylov, Uri; Al-Taweel, Talal; Yaghoobi, Mohammad; Bitton, Alain; Lakatos, Peter L.; Ben-Horin, Shomron; Seidman, Ernest G.; Afif, Waqqas

Book ID
122191804
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
251 KB
Volume
146
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Risk–benefit analysis of adalimumab vers
Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease
✍ Edward V. Loftus Jr; Scott J. Johnson; Si-Tien Wang; Eric Wu; Parvez M. Mulani; πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 474 KB πŸ‘ 1 views

Background: Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. Methods: A base-case analysis